SEARCH:   Advanced

Blood, 1 April 2004, Vol. 103, No. 7, pp. 2799-2801. Prepublished online as a Blood First Edition Paper on October 23, 2003; DOI 10.1182/blood-2003-06-1840. This Article Full Text Full Text (PDF) All Versions of this Article: 2003-06-1840v1 103/7/2799    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Rogers, A. Articles by Albitar, M. Search for Related Content PubMed PubMed Citation Articles by Rogers, A. Articles by Albitar, M. Related Collections Neoplasia Brief Reports Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  NEOPLASIA Brief report Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia Anna Rogers, Youngson Joe, Taghi Manshouri, Amanda Dey, Iman Jilani, Francis Giles, Elihu Estey, Emil Freireich, Michael Keating, Hagop Kantarjian, and Maher Albitar From the Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, and the Nichols Institute, Quest Diagnostics, San Juan Capistrano, CA. Using loss of heterozygosity (LOH) and X-chromosome inactivation, we compared peripheral blood (PB) plasma with bone marrow (BM) cells in detecting genomic abnormalities in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). We detected LOH in the PB plasma of all 45 patients who had cytogenetically documented chromosomal abnormalities (5q-, 7-, +8, 17-, or 20-). BM cells from the same patients showed LOH in 89% of patients with MDS and 70% of patients with AML. Posttherapy samples from 16 of these patients demonstrated complete concordance between LOH and cytogenetics in detecting residual disease in 15 samples. Of the 16 samples, 4 showed LOH in plasma with normal BM morphology. Using X-chromosome inactivation, clonality was detectable in 19 (73%) of 26 BM samples, whereas all PB plasma samples showed clonality. These data support the conclusion that PB plasma is enriched by tumor-specific DNA and can replace BM cells for studying genomic abnormalities. (Blood. 2004;103:2799-2801) CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: S. Hohaus, M. Giachelia, G. Massini, G. Mansueto, B. Vannata, V. Bozzoli, M. Criscuolo, F. D'Alo, M. Martini, L. M. Larocca, et al. Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas Ann. Onc., August 1, 2009; 20(8): 1408 - 1413. [Abstract] [Full Text] [PDF] W. Ma, H. Kantarjian, X. Zhang, W. Sun, A. M. Buller, I. Jilani, J. G. Schwartz, F. Giles, and M. Albitar Higher detection rate of JAK2 mutation using plasma Blood, April 1, 2008; 111(7): 3906 - 3907. [Full Text] [PDF] W. Ma, R. Tseng, M. Gorre, I. Jilani, M. Keating, H. Kantarjian, J. Cortes, S. O'Brien, F. Giles, and M. Albitar Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemia Haematologica, February 1, 2007; 92(2): 170 - 175. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020